Robot-assisted Versus Open Lateral Pancreaticojejunostomy for the Treatment of Symptomatic Chronic Pancreatitis (PANACOTTA)
Launched by ACADEMISCH MEDISCH CENTRUM - UNIVERSITEIT VAN AMSTERDAM (AMC-UVA) · Jul 31, 2025
Trial Information
Current as of August 19, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called PANACOTTA, is comparing two types of surgery to help people with chronic pancreatitis, a long-lasting inflammation of the pancreas that causes pain and other problems. The study looks at whether a newer, robot-assisted surgery is better than the traditional open surgery for a specific procedure called lateral pancreaticojejunostomy, which aims to relieve symptoms by improving drainage of the pancreas. Researchers want to see which method helps patients recover better after surgery.
People who might join this study are adults with chronic pancreatitis who have ongoing pain needing strong pain medicine or frequent flare-ups, and who have a widened main pancreatic duct. They need to be healthy enough for either type of surgery and must agree to take part in the study. If accepted, participants will be randomly assigned to have either the robot-assisted or open surgery and then doctors will carefully follow their recovery to compare outcomes. The trial is currently looking for volunteers aged 18 and older, regardless of gender. This study may help improve surgical options and recovery for people with chronic pancreatitis in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • At least 18 years old
- • Indication for (extended or partial) lateral pancreaticojejunostomy as agreed during multidisciplinary team meeting based on symptomatic chronic pancreatitis (i.e. morphine dependent pain or recurrent acute flares of pancreatitis, at least 3 episodes per year) and a dilated pancreatic duct of ≥ 5 mm, with a non-enlarged pancreatic head \< 40 mm
- • Confirmed CP, according to the M-ANNHEIM diagnostic Criteria24
- • Eligible for both an robot-assisted and open approach
- • Obtained written informed consent
- Exclusion Criteria:
- • Suspected or confirmed current pancreatic cancer
- • ASA classification ≥ 4
- • Other painful conditions aside from CP, with pain difficult to discriminate from CP pain
- • Prior pancreatic surgery
- • Pregnancy
About Academisch Medisch Centrum Universiteit Van Amsterdam (Amc Uva)
The Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) is a leading academic medical center in the Netherlands, dedicated to advancing healthcare through innovative research, education, and patient care. Affiliated with the University of Amsterdam, AMC-UvA integrates clinical practice with cutting-edge biomedical research, fostering a multidisciplinary approach to medical challenges. The institution actively engages in clinical trials to enhance treatment options and improve patient outcomes, while promoting collaboration among healthcare professionals, researchers, and academic institutions globally. With a commitment to excellence and a focus on translational medicine, AMC-UvA plays a pivotal role in shaping the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Amsterdam, , Netherlands
Patients applied
Trial Officials
M.G. Besselink, Amsterdam UMC
Principal Investigator
prof. dr.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported